Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry

por van de Laar, Celine J., Oude Voshaar, Martijn A. H., Vonkeman, Harald E.
Publicado 2019

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis

por Van De Laar, Celine J, Oude Voshaar, Martijn A H, Fakhouri, Walid K H, Zaremba-Pechmann, Liliana, De Leonardis, Francesco, De La Torre, Inmaculada, Van De Laar, Mart A F J
Publicado 2020